(Q39200153)

9 September 2017

title

Nabilone as an adjunctive to gabapentin for multiple sclerosis-induced neuropathic pain: a randomized controlled trial (English)

1 reference

9 September 2017

0 references

0 references

0 references

Dana Turcotte

1

1 reference

9 September 2017

Malcolm Doupe

2

1 reference

9 September 2017

Mahmoud Torabi

3

1 reference

9 September 2017

Andrew Gomori

4

1 reference

9 September 2017

Karen Ethans

5

1 reference

9 September 2017

Farid Esfahani

6

1 reference

9 September 2017

Katie Galloway

7

1 reference

9 September 2017

Mike Namaka

8

1 reference

9 September 2017

publication date

7 October 2014

1 reference

9 September 2017

1 reference

9 September 2017

volume

16

1 reference

9 September 2017

issue

1

1 reference

9 September 2017

page(s)

149-159

1 reference

The immune pathogenesis of multiple sclerosis.

9 September 2017

cites work

1 reference

Multiple sclerosis: molecular mechanisms and therapeutic opportunities

21 January 2018

1 reference

Experimental autoimmune encephalomyelitis-induced upregulation of tumor necrosis factor-alpha in the dorsal root ganglia.

21 January 2018

1 reference

NeuPSIG guidelines on neuropathic pain assessment

21 January 2018

1 reference

Neuronal mechanism for neuropathic pain

21 January 2018

1 reference

Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations

21 January 2018

1 reference

Clinically important changes in acute pain outcome measures: a validation study

21 January 2018

1 reference

Differential effects of neuropathic analgesics on wind-up-like pain and somatosensory function in healthy volunteers

21 January 2018

1 reference

Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial

21 January 2018

1 reference

Combination pharmacotherapy for the treatment of neuropathic pain in adults

21 January 2018

1 reference

Combined carbamazepine and pregabalin therapy in a rat model of neuropathic pain

21 January 2018

1 reference

Treatment of neuropathic pain: an overview of recent guidelines

21 January 2018

1 reference

A treatment algorithm for neuropathic pain: an update.

21 January 2018

1 reference

A randomized, controlled trial of gabapentin enacarbil in subjects with neuropathic pain associated with diabetic peripheral neuropathy

21 January 2018

1 reference

A randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of gabapentin enacarbil in subjects with neuropathic pain associated with postherpetic neuralgia (PXN110748).

21 January 2018

1 reference

21 January 2018

1 reference

Probable involvement of Ca(2+)-activated Cl(-) channels (CaCCs) in the activation of CB1 cannabinoid receptors

21 January 2018

1 reference

Endocannabinoid mechanisms of pain modulation

21 January 2018

1 reference

Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials

21 January 2018

1 reference

Nabilone for the treatment of pain in fibromyalgia

21 January 2018

1 reference

An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain

21 January 2018

1 reference

An open-label comparison of nabilone and gabapentin as adjuvant therapy or monotherapy in the management of neuropathic pain in patients with peripheral neuropathy

21 January 2018

1 reference

Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain : a double-blind placebo-controlled cross-over trial

21 January 2018

1 reference

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

21 January 2018

1 reference

Validity and reliability of the Spanish version of the DN4 (Douleur Neuropathique 4 questions) questionnaire for differential diagnosis of pain syndromes associated to a neuropathic or somatic component

21 January 2018

1 reference

Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4).

21 January 2018

1 reference

Core outcome measures for chronic pain clinical trials: IMMPACT recommendations

21 January 2018

1 reference

Contributions of change in clinical status parameters to Patient Global Impression of Change (PGIC) scores among persons with fibromyalgia treated with milnacipran

21 January 2018

1 reference

Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses.

21 January 2018

1 reference

Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study

21 January 2018

1 reference

A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis.

21 January 2018

1 reference

A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols).

21 January 2018

1 reference

Preoperative gabapentin for acute post-thoracotomy analgesia: a randomized, double-blinded, active placebo-controlled study

21 January 2018

1 reference

Morphine, gabapentin, or their combination for neuropathic pain.

21 January 2018

1 reference

Daily health status registration (patient diary) in patients with rheumatoid arthritis: a comparison between personal digital assistant and paper-pencil format

21 January 2018

1 reference

Electronic diaries as a tool to improve pain management: is there any evidence?

21 January 2018

1 reference

Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up.

21 January 2018

1 reference

Multiple sclerosis and extract of cannabis: results of the MUSEC trial.

21 January 2018

1 reference

Role of cannabinoids in multiple sclerosis

21 January 2018

1 reference

Cannabinoid receptor 2: potential role in immunomodulation and neuroinflammation

21 January 2018

1 reference

A cannabinoid agonist interferes with the progression of a chronic model of multiple sclerosis by downregulating adhesion molecules.

21 January 2018

1 reference

Neuroprotective agents: cannabinoids

21 January 2018

1 reference

Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects.

21 January 2018

1 reference

Examining the roles of cannabinoids in pain and other therapeutic indications: a review

21 January 2018

1 reference

Abuse potential of dronabinol (Marinol).

21 January 2018

1 reference

The abuse potential of the synthetic cannabinoid nabilone

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/PME.12569

1 reference

9 September 2017

1 reference